ArticleBriefings in bioinformatics2025
Growing and linking optimizers: synthesis-driven molecule design.
Article in Briefings in bioinformatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Combining Artificial Intelligence and Human Expertise in Pursuit of Novel PolQ Inhibitors.ACS omega · 2026Article
- From Algorithms to Assets: A Comprehensive Review of AI's Role in Preclinical Drug Discovery and the Hurdles to Clinical Translation.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Developments and challenges in hit progression within fragment-based drug discovery.Nature communications · 2026Review
- Artificial intelligence in drug discovery from advanced molecular representation to pipeline applications.Frontiers in bioinformatics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
In the present work, two reaction-based generative models for molecular design are presented: growing optimizer and linking optimizer. These models are designed to emulate real-life chemical synthesis by sequentially selecting building blocks and simulating the reactions between them to form new compounds. By focusing on the feasibility of the generated molecules, growing optimizer and linking optimizer offer several advantages, including the ability to restrict chemistry to specific building blocks, reaction types, and synthesis pathways, a crucial requirement in drug design. Unlike text-based models, which construct molecules by iteratively forming a textual representation of the molecular structure, and graph-based models, which assemble molecules atom by atom or fragment by fragment, our approach incorporates a more comprehensive understanding of chemical knowledge, making it relevant for drug discovery projects. Comparative analysis with REINVENT 4, a state-of-the-art molecular generative model, shows that growing optimizer and linking optimizer are more likely to produce synthetically accessible molecules while reaching molecules of interest with the desired properties.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.